Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Researchers define the genetic characteristics of ovarian tumors-- information that could lead to new opportunities for personalized therapy and may explain why screening programs for the disease haven’t been successful.
Did we bring this scary, painful, financially draining monster into our lives by eating too many cookies and not doing enough jumping jacks? We need a reliable diagnostic screening tool for ovarian cancer and we need it now.
Lenvima (lenvatinib) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, according to results from a phase I study.
Treatment with the combination of Keytruda (pembrolizumab), Avastin (bevacizumab) and metronomic cyclophosphamide appeared safe and effective in women with recurrent epithelial ovarian cancer, according to results from an open-label phase 2 study.